Table 3 MCDA outcomes for drug-indication pairs appraised by AHTAPol between 2007 and 2011 (economic criteria excluded)

1

Elaprase

2

2

1

2

2

2

1

1

13

2

Fabrazyme

2

2

2

2

2

0

1

1

12

THRESHOLD

75 %

12 points

3

Nexavar (HCC)

1

2

2

0

2

2

2

0

11

4

Kuvan

0

2

1

1

2

2

1

2

11

5

Nplate

2

1

0

2

2

2

1

1

11

6

Cystadane

2

2

2

0

0

2

0

2

10

7

Yondelis

1

1

2

2

0

2

2

0

10

8

Somavert

2

1

1

2

2

0

1

1

10

9

Tasigna

2

2

2

0

0

2

1

1

10

10

Increlex

2

0

0

2

2

2

1

1

10

11

Glivec – (GIST)

0

2

2

0

1

2

2

0

9

12

Revlimid (MM/S)

1

0

2

1

0

2

2

1

9

13

Glivec (DFSP)

0

2

2

0

1

2

1

1

9

14

Torisel

1

0

2

2

2

0

1

1

9

15

Ventavis

2

0

1

1

2

0

1

1

8

16

Zavesca

1

1

2

1

0

0

1

2

8

17

Tracleer

1

1

1

0

2

0

1

2

8

18

Volibris

2

2

0

1

0

0

1

2

8

19/20

Nexavar (RCC)

1

0

2

0

2

1

2

0

8

THRESHOLD

50 %

8 points

21

Vidaza

1

0

2

1

0

0

2

1

7

22

Sprycel

1

1

2

0

0

1

1

1

7

23

Revlimid (MM)

1

0

2

1

0

0

2

1

7

24

Atriance

1

0

2

1

0

2

1

0

7

25

Glivec (ALL Ph+)

0

1

2

0

1

0

1

0

5

26

Revatio

0

1

1

0

0

0

1

2

5

27

Glivec (MDS/MPD)

0

0

2

0

1

0

1

0

4

THRESHOLD

25 %

4 points